Advertisement

Acta Neurologica Belgica

, Volume 117, Issue 1, pp 103–109 | Cite as

Effectiveness of coenzyme Q10 in prophylactic treatment of migraine headache: an open-label, add-on, controlled trial

  • Ali Shoeibi
  • Nahid Olfati
  • Mohsen Soltani Sabi
  • Maryam Salehi
  • Sara Mali
  • Mahsa Akbari Oryani
Original Article

Abstract

Despite the huge health and economic burden of migraine headache, few medications have been approved for its prophylactic treatment, most of which can potentially induce serious adverse effects. Coenzyme Q10 (CoQ10) is a supplement and has shown preliminary benefits in migraine prophylaxis. We aimed to assess this effect in an adult population. This is an open-label, parallel, add-on, match-controlled trial. Eighty patients diagnosed with migraine headache based on International Headache Society criteria were allocated to receiving only their current preventive drugs or their current preventive drugs plus 100 mg CoQ10 daily, matching for their baseline characteristics, and were assessed for frequency and severity of attacks, and ≥50 % reduction in attack frequency per month. Thirty-six and 37 patients were analyzed in CoQ10 and control groups, respectively. Number of attacks per month dropped significantly in the CoQ10 group (mean decrease: 1.6 vs. 0.5 among CoQ10 and control groups, respectively, p < 0.001). A significant reduction was also evident in the severity of headaches (mean decrease: 2.3 vs. 0.6 among CoQ10 and control groups, respectively, p < 0.001). For ≥50 % reduction in the frequency of attacks per month, the number needed to treat was calculated as 1.6. No side effects for CoQ10 were observed. This study suggests that CoQ10 might reduce the frequency of headaches, and may also make them shorter in duration, and less severe, with a favorable safety profile.

Keywords

Coenzyme q10 Headache Migraine Prophylaxis 

Notes

Acknowledgments

We are thankful to the patients who participated in this study; we acknowledge Research Vice Chancellor of Mashhad University of Medical Sciences for funding and supporting this study.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical standard

Our study has been approved by Research Ethics Committee of Mashhad University of Medical Sciences.

Informed consent

Written informed consent was obtained from all participants before institution of trial.

References

  1. 1.
    Vos T, Flaxman AD, Naghavi M et al (2012) Years lived with disability (YLD) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2163–2196CrossRefPubMedGoogle Scholar
  2. 2.
    Hershey A, Powers S, Vockell A, LeCates S, Ellinor P, Segers A et al (2007) Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache 47(1):73–80CrossRefPubMedGoogle Scholar
  3. 3.
    Rozen T, Oshinsky M, Gebeline C, Bradley K, Young W, Shechter A et al (2002) Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 22(2):137–141CrossRefPubMedGoogle Scholar
  4. 4.
    Sándor PS, Di Clemente L, Coppola G, Saenger U, Fumal A, Magis D et al (2005) Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 64(4):713–715CrossRefPubMedGoogle Scholar
  5. 5.
    Gaul C, Diener H-C, Danesch U (2015) Improvement of migraine symptoms with a proprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial. J Headache Pain 16(1):32CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Slater SK, Nelson TD, Kabbouche MA, LeCates SL, Horn P, Segers A et al (2011) A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia 31:897–905CrossRefPubMedGoogle Scholar
  7. 7.
    Sasannejad P, Saeedi M, Shoeibi A, Gorji A, Abbasi M, Foroughipour M (2012) Lavender essential oil in the treatment of migraine headache: a placebo-controlled clinical trial. Eur Neurol 67(5):288–291CrossRefPubMedGoogle Scholar
  8. 8.
    Pagano G, Talamanca A, Castello G, Cordero M, d’ Ischia M, Gadaleta M et al (2014) Current experience in testing mitochondrial nutrients in disorders featuring oxidative stress and mitochondrial dysfunction: rational design of chemoprevention trials. Int J Mol Sci 15(11):20169–20208. doi: 10.3390/ijms151120169 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Garrido-Maraver J, Cordero MD, Oropesa-Ávila M, Vega A, Mata M, Pavón A et al (2014) Coenzyme Q10 therapy. Mol Syndromol 5(3–4):187–197PubMedPubMedCentralGoogle Scholar
  10. 10.
    Sparaco M, Feleppa M, Lipton R, Rapoport A, Bigal M (2006) Mitochondrial dysfunction and migraine: evidence and hypotheses. Cephalalgia 26(4):361–372CrossRefPubMedGoogle Scholar
  11. 11.
    Sadeghi O, Nasiri M, Saiedi S (2015) The prevalence of migraine in different parts of Iran: review of the current evidence. Jundishapur J Chronic Dis Care 4(3):e27678CrossRefGoogle Scholar
  12. 12.
    Headache Classification Committee of the International Headache Society (IHS) (2013) The international classification of headache disorders, 3rd edn (beta version). Cephalalgia 33(9):629–808Google Scholar
  13. 13.
    Yorns WR, Hardison HH (2013) Mitochondrial dysfunction in migraine. Semin Pediatr Neurol 20:188–193CrossRefPubMedGoogle Scholar
  14. 14.
    Roos-Araujo D, Stuart S, Lea RA, Haupt LM (2014) Epigenetics and migraine; complex mitochondrial interactions contributing to disease susceptibility. Gene 543(1):1–7CrossRefPubMedGoogle Scholar
  15. 15.
    Fried NT, Moffat C, Seifert EL, Oshinsky ML (2014) Functional mitochondrial analysis in acute brain sections from adult rats reveals mitochondrial dysfunction in a rat model of migraine. Am J Physiol Cell Physiol 307:C1017–C1030CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Okada H, Araga S, Takeshima T, Nakashima K (1998) Plasma lactic acid and pyruvic acid levels in migraine and tension-type headache. Headache 38:39–42CrossRefPubMedGoogle Scholar
  17. 17.
    Zaki EA, Freilinger T, Klopstock T, Baldwin EE, Heisner KR, Adams K et al (2009) Two common mitochondrial DNA polymorphisms are highly associated with migraine headache and cyclic vomiting syndrome. Cephalalgia 29:719–728CrossRefPubMedGoogle Scholar
  18. 18.
    Di Lorenzo C, Pierelli F, Coppola G, Grieco GS, Rengo C, Ciccolella M et al (2009) Mitochondrial DNA haplogroups influence the therapeutic response to riboflavin in migraineurs. Neurology 72:1588–1594CrossRefPubMedGoogle Scholar
  19. 19.
    Stuart S, Griffiths LR (2012) A possible role for mitochondrial dysfunction in migraine. Mol Genet Genomics 287:837–844CrossRefPubMedGoogle Scholar
  20. 20.
    Welch K, Levine SR, D’andrea G, Schultz LR, Helpern JA (1989) Preliminary observations on brain energy metabolism in migraine studied by in vivo phosphorus 31 NMR spectroscopy. Neurology 39:538CrossRefPubMedGoogle Scholar
  21. 21.
    Sparaco M, Feleppa M, Lipton RB, Rapoport AM, Bigal ME (2006) Mitochondrial dysfunction and migraine: evidence and hypotheses. Cephalalgia 26:361–372CrossRefPubMedGoogle Scholar

Copyright information

© Belgian Neurological Society 2016

Authors and Affiliations

  1. 1.Department of NeurologyMashhad University of Medical SciencesMashhadIran
  2. 2.Department of Community MedicineMashhad University of Medical SciencesMashhadIran
  3. 3.Department of PathologyMashhad University of Medical SciencesMashhadIran

Personalised recommendations